pyctx.com | ACN 098 391 961 1 11 September 2026 POLYCYSTIC KIDNEY DISEASE – FIRST PATIENT DOSED IN OPEN LABEL EXTENSION STUDY • PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available • The Company is...
PKD - First Patient Dosed in OLE Study
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- S&P DJI Announces September 2026 Quarterly Rebalance
- Investor Webinar Presentation Q3 2026
- ADOA Program - Data Presentation
- Ceasing to be a substantial holder
- PKD - Presentation of Clinical Safety Data
Later from PYC Therapeutics
- RP11 program - presentation at euretina 2026
- PKD Program - Presentation of Data at ASN Conference
- Notification of cessation of securities - PYC
- Application for quotation of securities - PYC
- Notice of Annual General Meeting/Proxy Form
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics